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Purpose: Chronic low back pain is a common clinical problem. As medication, 
non-steroidal anti-inflammatory drugs are generally used; however, they are some-
times non-effective. Recently, opioids have been used for the treatment of chronic 
low back pain, and since 2010, transdermal fentanyl has been used to treat chronic 
non-cancer pain in Japan. The purpose of the current study was to examine the effi-
cacy of transdermal fentanyl in the treatment of chronic low back pain. Materials 
and Methods: This study included patients (n=62) that suffered from chronic low 
back pain and were non-responsive to non-steroidal anti-inflammatory drugs. Their 
conditions consisted of non-specific low back pain, multiple back operations, and 
specific low back pain awaiting surgery. Patients were given transdermal fentanyl 
for chronic low back pain. Scores of the visual analogue scale and the Oswestry 
Disability Index, as well as adverse events were evaluated before and after therapy. 
Results: Overall, visual analogue scale scores and Oswestry Disability Index scores 
improved significantly after treatment. Transdermal fentanyl (12.5 to 50 μg/h) was 
effective in reducing low back pain in 45 of 62 patients; however, it was not effec-
tive in 17 patients. Patients who experienced the most improvement were those 
with specific low back pain awaiting surgery. Adverse events were seen in 40% of 
patients (constipation, 29%; nausea, 24%; itching, 24%). Conclusion: Transdermal 
fentanyl significantly improved visual analog scale scores and Oswestry Disability 
Index scores in 73% of patients, especially those with specific low back pain await-
ing surgery; however, it did not decrease pain in 27% of patients, including patients 
with non-specific low back pain or multiple back operations.
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INTRODUCTION
Low back pain (LBP) is a common clinical problem and is of major socioeconomic 
importance. Although any of the spinal structures (intervertebral discs, facet joints, 
vertebral bodies, ligaments, and muscles) may be a source of LBP, the most likely 
cause is unclear.
Treatment for chronic LBP includes conservative therapy (exercise), intradiscal 
electrothermal therapy, spinal fusion, and artificial disc replacement. Several ran-Transdermal Fentanyl for LBP
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Demographic characteristics
Table 1 shows patient demographic characteristics. The pain 
score was severe in all patients. All patients used NSAIDs; 
however, NSAIDs were not effective for LBP. The diagno-
sis was non-specific chronic LBP in 20 patients, LBP after 
single lumbar surgery in 15 patients, and multiple back op-
erations in 15 patients. There were 12 patients who were 
awaiting lumbar surgery, including lumbar disc herniation 
and spinal canal stenosis, and had severe specific LBP. The 
patients were enrolled consecutively and were opioid-naïve.
Medication
A transdermal fentanyl patch (Janssen, Tokyo, Japan) was 
applied to all patients for the treatment of LBP. The patch 
was changed every three days. The starting dose was 12.5 
μg/h. If this dose was not effective, it was increased to 25, 
37.5 and 50 μg/h, thereafter. If one dose was non-effective 
for six days, the next highest dose patch was applied for six 
days. The maximum dose was 50 μg/h. If the patient’s visu-
al analogue scale (VAS) score did not decrease by 20%, we 
defined the medication as “non-effective”.
Conservative treatment included exercise (walking, walk-
ing in a pool, muscle training, and muscle stretching). Walk-
ing and walking in a pool were performed by the patients 
on their own. Muscle training and stretching was performed 
for the abdomen and lower extremities by physical thera-
pists. Medications, except for transdermal fentanyl, were 
allowed. Medications included NSAIDs, vitamins, muscle 
relaxants, and prostaglandin E1. A physician decided the 
type of medication for each patient.
domized trials have compared surgical and nonsurgical 
treatment of chronic LBP and have arrived at conflicting 
conclusions.1,2 Typical pharmacologic therapy of LBP be-
gins with non-steroidal anti-inflammatory drug (NSAIDs) 
administration. NSAIDs are useful for mild to moderate 
LBP; however, they are not effective for severe LBP. Fur-
thermore, they have a high risk of serious gastrointestinal 
bleeding.3 
Oral morphine has been available for decades and is of-
ten used as a reference against which other treatments are 
compared.4 Patients with severe chronic LBP may require 
oral morphine for effective pain management. The use of 
oral morphine for treating chronic LBP has been increasing 
in recent years. However, adverse events and risk of addic-
tion from the extended use of opioid therapy are concerns 
with this approach.5 
Transdermal fentanyl may offer advantages over oral mor-
phine and may be preferred by patients.6 Several large studies 
have demonstrated the efficacy and safety of transdermal 
fentanyl in patients with non-cancer pain.6,7 A controlled-re-
leased transdermal therapeutic system can provide systemic 
delivery of fentanyl at a constant rate for up to 72 hr.8 
Since 2010, transdermal fentanyl was available for use in 
Japan to treat chronic non-cancer pain; however, its use in 
the treatment of chronic LBP has not been reported. The 
purpose of the current study was to examine the efficacy 
and tolerability of transdermal fentanyl for the treatment of 
chronic LBP in a Japanese population. 
MATERIALS AND METHODS
　　　
The ethics committee of our institution approved the proto-
col for the human procedures used in this study. Further-
more, the protocol and publication of the study were ap-
proved by our institutional review board. This trial was a 
prospective trial. The patients who participated in this study 
were selected from outpatients who attended our hospital 
for LBP. These 62 patients were selected from 412 LBP pa-
tients matched to the following criteria.
All patients had LBP for more than three months and 
were resistant to treatment with oral NSAIDs. Informed 
consent was obtained from each of the participants. Pa-
tients had non-specific chronic LBP, chronic LBP after 
lumbar surgery, multiple back operations, and specific 
LBP awaiting surgery (e.g., lumbar disc herniation or spi-
nal stenosis). 
Table 1. Demographic Characteristics
Number of patients 62
Sex Male: 30, Female: 32
Age mean range (range), yrs 62±8.0 (24-80)
Symptom duration, mean (range), yrs 5.5 (1-10)
Pain score before treatment
Low back pain
    Visual analogue scale 8.4±1.5
    Oswestry Disability Index 54±10
Use of NSAIDs 62
Diagnosis
    Non specific chronic low back pain 20 (32%)
    Low back pain after single lumbar 
      surgery 15 (24%)
    Multiple back operations 15 (24%)
    Specific LBP awaiting surgery 
      (e.g., lumbar disc herniation or spinal 
      stenosis)
12 (20%)
NSAIDs, non-steroidal anti-inflammatory drug.Seiji Ohtori, et al.
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was considered statistically significant.
RESULTS  
Dosage of transdermal fentanyl
Table 2 shows the dosage of transdermal fentanyl adminis-
tered. The patients were administered doses from 12.5 to 50 
μg/h. Most patients were administered 12.5 μg/h of trans-
dermal fentanyl. The average dosage was 19.6±1.8 μg/h 
(mean±S.E.M.).
 
Evaluation of LBP after treatment
Table 3 shows the results of the evaluation of LBP after 
treatment in all 62 patients. VAS and ODI one month after 
treatment were 5.0±0.3 (mean±S.E.M.) and 32±6, respec-
tively, and were significantly less than that before treatment 
(p<0.01). Mean VAS score and ODI score at final follow-
up were 4.6±0.3 and 28±6, respectively, and were signifi-
cantly lower than values obtained before treatment (p<0.01). 
Transdermal fentanyl was very effective, especially in all 
patients with specific LBP awaiting surgery, so we divided 
the patients into the following three groups: 1) transdermal 
fentanyl was effective (responders), n=32; 2) transdermal 
fentanyl was effective in patients awaiting surgery (respond-
ers), n=12; and 3) transdermal fentanyl was not effective 
(non-responders), n=18 (Table 4). VAS scores and ODI 
scores were significantly lower after treatment than before 
treatment in the two responder groups (p<0.05). Also, VAS 
scores and ODI scores after treatment in the two responder 
groups were significantly lower than those of the non-re-
sponder group (p<0.05). However, pain scores one month 
after treatment and at final follow-up were not significantly 
lower than those of the non-responder group before treat-
ment (p>0.05) (Fig. 1). On the other hand, transdermal fen-
tanyl was more effective in the responders awaiting surgery 
compared with the other responders (p<0.05) (Fig. 2).  
The average duration of treatment was significantly short-
er in the non-responder group compared with the responder 
groups, because non-responders did want to continue with 
the transdermal fentanyl therapy (p<0.05) (Table 4). The 
Evaluation of pain score
We evaluated LBP before treatment, one month after treat-
ment, and at final follow-up. Pain scores in patients with spe-
cific LBP awaiting surgery was evaluated at seven days be-
fore their surgery, which was considered as their final follow-
up. If a patient stopped the medication (e.g., non-responder), 
the pain evaluation from seven days before the last dose was 
administered was recorded. For the evaluation of pain in all 
patients, scores from the VAS score (0, no pain; 10, worst 
pain) and the Oswestry Disability Index (ODI) score (0, no 
pain; 100, worst pain) were recorded and compared.
Subjective outcomes
At four months after treatment, patients were asked to choose 
one of the following responses regarding their satisfaction 
with the treatment: 1) the medication met my expectations; 
2) I did not improve as much as I had hoped, but I would 
undergo the same medication for the same outcome; 3) the 
medication helped, but I would not undergo the same medi-
cation for the same outcome; or 4) I am the same as or 
worse than I was before the medication.
Adverse events
All adverse events were reported together with an assess-
ment of their severity (mild, moderate, severe) and the in-
vestigator’s opinion of their relationship to treatment with 
transdermal fentanyl (none, unlikely, possible, or probable). 
Antiemetics were used in all patients. Laxatives were pre-
scribed for constipation. Addiction was measured accord-
ing to previous reports.9 
    
Statistical analysis
Data were compared with the Mann-Whitney U-test. p<0.05 
Table 2. Dosage of Transdermal Fentanyl
Dosage Number of patients
µg/hrs
    12.5 41 (66%)
    25 14 (23%)
    37.5 2 (3%)
    50 5 (8%)
    >50 0
Average dosage 19.64±1.8 µg/hrs
Table 3. Pain after Treatment
All patients (n=62) Pain score before 
treatment
Pain score 1month 
after treatment
Pain score after 
treatment (final) p value
Low back pain
    Visual analogue scale 8.4±1.5*   5.0±0.3
†   4.6±0.3
‡ *
,†p<0.01,  *
,‡p<0.01
    Oswestry Disability Index 54±10* 32±6
† 28±6
‡ *
,†p<0.01,  *
,‡p<0.01Transdermal Fentanyl for LBP
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The most common adverse events were constipation, nau-
sea, itching, and somnolence. Adverse events were mild in 
all patients. Itching was seen as a local reaction to the trans-
dermal fentanyl patch. One patient (2%) showed withdraw-
al symptoms (loss of appetite and motivation) after stop-
ping the transdermal fentanyl patch. However, addiction 
was not seen in any patient.
DISCUSSION
This is first study to evaluate the efficacy of transdermal fen-
tanyl for the treatment of chronic LBP in a Japanese popula-
tion. In general, transdermal fentanyl significantly improved 
average dosage of transdermal fentanyl in the non-respond-
er group was significantly higher than that in each of the re-
sponder groups, because of the insufficiency of the drug 
(p<0.05) (Table 4).
Subjective outcomes
Details of subjective outcomes after treatment are presented 
in Table 5. Subjective outcomes were good and fair in 27 
and 15 patients, respectively; however, 12 patients and 8 
patients reported an unexpected or poor outcome.
Adverse events
Table 6 shows the adverse events reported throughout fol-
low-up. Adverse events were seen in 40% of all 62 patients. 
Table 4. Pain after Treatment
Responder 
(effective)
Responder (effective) 
(awaiting surgery)
Non-responder 
(non-effective) p value
Number of patients 32 12 18
Pain before treatment
    Visual analogue scale   8.4±0.2   8.8±0.4    8.2±0.2 N.S.
    Oswestry Disability Index   50±10   58±12  52±8 N.S.
Pain 1month after treatment
    Visual analogue scale     4.0±0.2*    2.6±0.4
†     6.5±0.5
‡ *
,†p<0.05, *
,‡p<0.05, 
†,‡p<0.01 
    Oswestry Disability Index   28±7*  18±6
†     50±10
‡ *
,†p<0.05, *
,‡p<0.05, 
†,‡p<0.01 
Pain after treatment (final)
    Visual analogue scale     3.9±0.2*    2.5±0.3
†     6.9±0.4
‡ *
,†p<0.05, *
,‡p<0.05, 
†,‡p<0.01 
    Oswestry Disability Index   25±7*  16±4
†   46±8
‡ *
,†p<0.05, *
,‡p<0.05, 
†,‡p<0.01 
Period of treatment (months)     7.1±0.9*    3.1±0.3
†     2.5±0.7
‡ *
,†p<0.01, *
,‡p<0.01, 
†,‡p<0.05 
Dosage of transdermal fentanyl (µg/hrs) 19.64±1.8* 14.88±1.2* 23.81±3.6
† *
,†p<0.05, *
,‡p<0.05, 
†,‡p<0.05 
Fig. 1. VAS scores in responders and non-responders. Month 0=before 
treatment. VAS scores after treatment were significantly lower than those 
before treatment in the responder group at each time point (p<0.01). 
However, pain scores one month after treatment and at final follow-up did 
not differ significantly from those before treatment in the non-responder 
group (p>0.05). VAS, visual analogue scale.
Fig. 2. VAS scores in responders and non-responders. Month 0=before 
treatment. VAS scores after treatment in the two responder groups were 
significantly lower than those in the non-responder group at each time 
point (p<0.05). VAS scores after treatment indicated that transdermal fen-
tanyl was more effective in the responders awaiting surgery compared 
with the other responders at each time point (p<0.05). VAS, visual analogue 
scale.
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ed with less constipation compared with sustained-release 
morphine. Kosinski, et al.14 reported the efficacy of trans-
dermal fentanyl in patients with chronic LBP and compared 
pain relief and patient’s health-related quality of life score 
improvement. Health-related quality of life score improve-
ment was greatest among patients experiencing the greatest 
pain relief from transdermal fentanyl. In the current study, 
transdermal fentanyl significantly improved VAS scores 
and ODI scores in Japanese patients with chronic LBP, and 
these findings are similar to those of other studies. 
In the current study, transdermal fentanyl was more ef-
fective in patients who were awaiting surgery and had spe-
cific LBP due to apparent disc herniation or spinal stenosis, 
compared with the other responders or non-responders. 
Non-responders included patients with non-specific LBP 
and LBP after surgery, but did not include patients with 
specific LBP. Transdermal fentanyl was not effective at one 
month and final follow-up in non-responders. Furthermore, 
the average dosage of transdermal fentanyl was significant-
ly higher in the non-responder group than in the responder 
groups because of the insufficiency of the drug. In a previ-
ous study, it was reported that there were no differences in 
age, sex, and type or duration of pain between responders 
and non-responders after the application of transdermal 
fentanyl.15 The difference in response to treatment between 
responders and non-responders could be detected at three 
weeks.15 Lack of response after one month had a stronger 
negative predictive value than the presence of response af-
ter one month. The most influential factors for predicting a 
response were employment status and use of high doses of 
opioids.15 Considering previous reports and the results of 
the current study, a lack of response after one month and 
use of a high dosage of opioids may have a negative predic-
tive value for response to opioids.
Kalso, et al.16 analyzed available randomized, placebo-
controlled trials of opioids for efficacy and safety in patients 
with chronic non-cancer pain. About 80% of patients experi-
enced at least one adverse event, with constipation (41%), 
nausea (32%) and somnolence (29%) being the most com-
mon.16 As most of the studies analyzed were short-term fol-
VAS scores and ODI scores in patients with chronic LBP, 
especially in patients with specific LBP awaiting surgery; 
however, it did not decrease pain in 27% of the patients with 
non-specific LBP or multiple back operations. Adverse 
events were seen in 40% of patients; however, no addiction 
was seen.
It has been reported that both weak and strong opioids 
are effective in the treatment of chronic LBP. Three double-
blind RCTs compared opioids to an inactive placebo in the 
management of chronic LBP.10-12 In one US trial, 380 out-
patients with chronic LBP were enrolled in an open-label 
phase study and treated with tramadol, followed by enroll-
ment of those who tolerated tramadol into a double-blind, 
placebo-controlled phase study.10 Patients treated with tra-
madol scored significantly better on the VAS, the McGill 
Pain Questionnaire and the Roland Disability Question-
naire.10 In another US trial, patients with LBP were random-
ized to receive either tramadol/acetaminophen or a placebo 
for 91 days. Tramadol/acetaminophen significantly im-
proved the final scores for VAS, the Roland Disability Ques-
tionnaire, and a 36-Item Short-Form Health Survey from 
baseline levels.11 In the third trial, 333 patients with chronic 
LBP were randomized to receive tramadol/acetaminophen 
or a placebo in Canada. The tramadol/acetaminophen com-
bination showed efficacy in pain reduction, measures of 
physical functioning and quality of life.12 
Several authors have reported the effectiveness of trans-
dermal fentanyl for the treatment of chronic LBP.11,12 Allan, 
et al.13 compared the efficacy and safety of transdermal fen-
tanyl and sustained-release morphine in strong-opioid-na-
ïve patients with chronic LBP. Transdermal fentanyl was 
effective in the treatment of chronic LBP and was associat-
Table 5. Subjective Outcomes (Number of Patients)
Number of patients (%)
Treatment met my expectations 27 (44)
I did not improve as much as I had hoped, but I would undergo the same treatment for the same outcome 15 (24)
Treatment helped, but I would not undergo the same treatment for the same outcome 12 (19)
I am the same as or worse than I was before the treatment   8 (13)
Table 6. Adverse Events
Number of patients (%)
Constipation 18 (29)
Nausea 15 (25)
Itching 15 (25)
Somnolence 11 (18)
Withdrawal 1 (2)
Addiction 0 (0)Transdermal Fentanyl for LBP
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scription medication dependence and neuropsychologic function. 
Pain 1984;18:169-77.
6. Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, 
et al. Randomised crossover trial of transdermal fentanyl and sus-
tained release oral morphine for treating chronic non-cancer pain. 
BMJ 2001;322:1154-8.
7. Franco ML, Seoane A. Usefulness of transdermal fentanyl in the 
management of nonmalignant chronic pain: a prospective, obser-
vational, multicenter study. Pain Clinic 2002;14:99-112.
8. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharma-
cological properties and therapeutic efficacy in pain control. Drugs 
1997;53:109-38.
9. Adams LL, Gatchel RJ, Robinson RC, Polatin P, Gajraj N, Desch-
ner M, et al. Development of a self-report screening instrument for 
assessing potential opioid medication misuse in chronic pain pa-
tients. J Pain Symptom Manage 2004;27:440-59.
10. Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramad-
ol in treatment of chronic low back pain. J Rheumatol 2000;27: 
772-8.
11. Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M; Protocol 
CAPSS-112 Study Group. Tramadol/acetaminophen combination 
tablets for the treatment of chronic lower back pain: a multicenter, 
randomized, double-blind, placebo-controlled outpatient study. 
Clin Ther 2003;25:1123-41.
12. Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal N; Proto-
col TRP-CAN-1 Study Group. Analgesic efficacy and safety of 
tramadol/ acetaminophen combination tablets (Ultracet) in treat-
ment of chronic low back pain: a multicenter, outpatient, random-
ized, double blind, placebo controlled trial. J Rheumatol 2004;31: 
2454-63.
13. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fen-
tanyl versus sustained release oral morphine in strong-opioid na-
ïve patients with chronic low back pain. Spine (Phila Pa 1976) 
2005;30:2484-90.
14. Kosinski MR, Schein JR, Vallow SM, Ascher S, Harte C, Shikiar 
R, et al. An observational study of health-related quality of life and 
pain outcomes in chronic low back pain patients treated with fen-
tanyl transdermal system. Curr Med Res Opin 2005;21:849-62.
15. Kalso E, Simpson KH, Slappendel R, Dejonckheere J, Richarz U. 
Predicting long-term response to strong opioids in patients with 
low back pain: findings from a randomized, controlled trial of 
transdermal fentanyl and morphine. BMC Med 2007;5:39.
16. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic 
non-cancer pain: systematic review of efficacy and safety. Pain 
2004;112:372-80.
17. Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales KH, 
Kosten TR, et al. Systematic review: opioid treatment for chronic 
back pain: prevalence, efficacy, and association with addiction. 
Ann Intern Med 2007;146:116-27.
low-up studies, they did not allow for conclusions to be 
made concerning problems with tolerance and addiction.16 
A systematic review revealed that opioids are commonly 
prescribed for chronic LBP and may be efficacious for 
short-term pain relief, but their long-term efficacy is un-
clear.17 Substance use disorders are common in patients tak-
ing opioids for back pain, and aberrant medication-taking 
behaviors occur in 5 to 24% of cases.15 In the current study, 
the most common adverse events reported were constipa-
tion, nausea, itching, and somnolence; however, addiction 
was not documented in any patient. The current results may 
be due to the short-term follow-up period of the study.
In conclusion, we evaluated the efficacy of transdermal 
fentanyl for severe chronic LBP in a Japanese population. 
Transdermal fentanyl significantly improved pain scores in 
73% of patients with LBP; however, about 27% of patients 
demonstrated a non-response. Non-responders included pa-
tients with non-specific LBP and pain after lumbar surgery. 
Treatment was most effective in patients with specific LBP 
awaiting surgery, and pain relief was seen in all patients in 
that group. Adverse events were reported in 40% of all of the 
patients. In patients with chronic LBP resistant to NSAIDs, 
transdermal fentanyl may be a good therapeutic agent to re-
duce pain.  
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